1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Evotec SE

Evotec SE

EVOTF
Evotec SEUS flagOther OTC
6.69
USD
- -
- -
1.19BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.71
0.68
0.97
1.24
1.82
2.55
2.98
3.26
3.71
4.25
4.42
4.5
4.44
4.04
Basic EPS, GAAP
-0.21
-0.05
0.13
0.21
0.16
0.57
0.25
0.04
1.3
-0.99
-0.47
-1.11
-0.58
-1.11
Free Cash Flow per Basic Share
0.01
-0.07
0.03
0.43
-0.05
0.87
0.07
-0.35
0.05
0.14
-1.01
-0.64
-0.52
-0.98
Dividend per Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.21
1.2
1.4
1.6
2.25
2.85
3.17
4.43
7.8
6.71
6.32
5.36
4.59
3.75
Tangible Book Value per Share
0.6
0.63
0.87
0.71
-0.17
0.54
0.69
2.32
6.17
5.02
4.68
3.62
2.87
2.02
Basic Weighted Avg Shares
121
131
132
133
145
147
150
154
166
177
177
177
178
178
Sales/Revenue/Turnover
86
89
128
165
264
375
446
501
618
751
781
797
788
717
Operating Margin (%)
4.85
2.24
-1.98
22.34
13.22
17.69
16.72
10.34
6.74
2.77
-3.41
-9.9
-7.08
-19.96
Depreciation Expense
9
9
12
12
21
31
49
56
70
83
93
102
99
- -
Net Income, GAAP
-25
-7
17
28
23
84
38
6
216
-176
-84
-196
-104
-197
Effective Tax Rate (%)
- -
- -
- -
18.55
9.18
- -
34.16
75.7
9.06
- -
- -
- -
- -
50.37
Profit Margin (%)
-29.59
-7.8
12.94
16.73
8.9
22.42
8.55
1.25
34.87
-23.38
-10.74
-24.6
-13.13
-27.47
Working Capital
84
92
111
96
-65
53
291
450
776
736
439
337
395
416
LT Debt
- -
8
9
7
21
58
442
462
462
490
477
393
344
414
Total Equity
159
158
187
214
332
425
477
724
1,378
1,187
1,120
953
814
666
Return on Invested Capital (%)
- -
- -
- -
13.19
8.26
- -
6.6
1.16
2.43
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
13.01
6.51
- -
5.94
0.77
14.41
- -
- -
- -
- -
-6.12
Return on Common Equity (%)
-16.33
-4.4
9.61
13.82
8.63
22.3
8.47
1.05
20.5
-13.7
-7.27
-18.92
-11.72
-26.08

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
62
LT Borrowings
344
299
414
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
177
178
178
Market Capitalization
1,210
805
1,040

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
763
711
729
Cash, Cash Equivalents & STI
463
464
484
Accounts Receivable, Net
136
98
96
Inventories
29
33
39
Total Current Liabilities
368
423
312
Payables & Accruals
81
64
58
ST Debt
- -
- -
62
Deferred Revenue
108
115
73

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.28%
8.23%
-14.57%
Free Cash Flow
-233.81%
-156.96%
-19.48%
Net Income, GAAP
335.78%
637.1%
-47.21%
Sales/Revenue/Turnover
21.25%
9.97%
-1.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
209
182
185
221
797
2025
200
171
164
253
788
2026
157
143
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.54
-0.22
- -
-1.11
2025
-0.18
-0.24
- -
- -
-0.58
2026
-0.69
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christian Wojczewski
Full Time Employees
4,553
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Essener Bogen 7 Hamburg HA Germany 22419
IPO Date
Oct 7, 2009
CIK
0001412558
Website
evotec.com
Similar Companies
TerrAscend Corp. (TSND.TO)
SciClone Pharmaceuticals, Inc. (SCLN)
Mithra Pharmaceuticals S.A. (MITRA.BR)
Amryt Pharma plc (AMYT.L)
Biome Grow Inc. (BIOIF)
The Green Organic Dutchman Holdings Ltd. (TGODF)
Business
Evotec SE functions as a global drug discovery and development partner, collaborating with the pharmaceutical and biotechnology sectors internationally. The company actively advances pharmaceutical programs across a broad spectrum of therapeutic areas, encompassing oncology, autoimmune conditions, diabetes, heart failure, immunology, pain and inflammation, infectious diseases, kidney and liver disorders, respiratory ailments, fibrotic and metabolic conditions, rare diseases, central nervous system maladies, cardiometabolic conditions, and women's health. It delivers comprehensive solutions spanning the entire drug discovery and preclinical development process, from identifying targets to manufacturing biologics. Evotec maintains key collaborations with leading entities such as Bristol Myers Squibb in protein degradation and neuroscience, Pfizer for metabolic and infectious diseases, and Novo Nordisk in cell therapy. Recent activities include expanding partnerships and the sale of its Just – Evotec Biologics Toulouse site to Sandoz AG as part of a long-term biosimilars technology agreement in late 2025. Originally established in 1993, the company adopted the name Evotec SE in April 2019 and is based in Hamburg, Germany.

Company News

Company News APIChatGPT